Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

An Open-Label, 2-Part Study to Investigate the Effect of Lasmiditan on the Pharmacokinetics of Dabigatran and Rosuvastatin in Healthy Volunteers

Next Previous
Trial Profile

An Open-Label, 2-Part Study to Investigate the Effect of Lasmiditan on the Pharmacokinetics of Dabigatran and Rosuvastatin in Healthy Volunteers

Status: Completed
Phase of Trial: Phase I

Latest Information Update: 07 Feb 2024

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Lasmiditan (Primary) ; Dabigatran etexilate; Rosuvastatin
  • Indications Migraine
  • Focus Pharmacokinetics
  • Sponsors Eli Lilly and Company

Most Recent Events

  • 12 Jun 2022 Results assessing pharmacokinetics (PK) of probe substrates for P- gp (dabigatran etexilate) and BCRP (rosuvas-tatin) alone and in the presence of lasmiditan in healthy volunteers presented at the 64th Annual Scientific Meeting of the American Headache Society
  • 16 Jul 2021 Status changed from active, no longer recruiting to completed.
  • 06 Jul 2021 Status changed from not yet recruiting to active, no longer recruiting.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top